to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells.
A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.
Protein kinase C beta in malignant pleural mesothelioma.
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.
Ethnic differences and functional analysis of MET mutations in lung cancer.
Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion.
c-Met is a potentially new therapeutic target for treatment of human melanoma.
A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer.
Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.
Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.
Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors.